| Particulars (Rupees in Crores.) | Mar-2025 | Sept-2024 | Mar-2024 | Sept-2023 | Mar-2023 | 
|---|---|---|---|---|---|
Gross Sales  | 296.02  | 263.07  | 286.96  | 272.21  | 244.13  | 
Excise Duty  | 0  | 0  | 0  | 0  | 0  | 
Net Sales  | 296.02  | 263.07  | 286.96  | 272.21  | 244.13  | 
Other Operating Income  | 0  | 0  | 0  | 0  | 0  | 
Other Income  | 42.69  | 13.96  | 22.01  | 39.82  | 76.15  | 
Total Income  | 338.71  | 277.03  | 308.97  | 312.03  | 320.28  | 
Total Expenditure  | 314.94  | 270.06  | 293.15  | 286.08  | 258.44  | 
PBIDT  | 23.77  | 6.97  | 15.82  | 25.95  | 61.84  | 
Interest  | 2.03  | 1.85  | 1.67  | 1.91  | 2.01  | 
PBDT  | 21.74  | 5.12  | 14.15  | 24.04  | 59.83  | 
Depreciation  | 17.4  | 17.41  | 17.92  | 18.79  | 19.18  | 
Minority Interest Before NP  | 0  | 0  | 0  | 0  | 0  | 
Tax  | 0.01  | 0  | 0.69  | 0  | 2.56  | 
Deferred Tax  | 1.88  | -1.12  | -0.27  | 2.56  | 31.4  | 
Reported Profit After Tax  | 2.45  | -11.17  | -4.19  | 2.69  | 6.69  | 
Minority Interest After NP  | -0.35  | 0  | -0.33  | 0  | 0  | 
Net Profit after Minority Interest  | 2.8  | -11.17  | -3.86  | 2.69  | 6.69  | 
Extra-ordinary Items  | 30.48  | 5.51  | 5.52  | 27.95  | 47.15  | 
Adjusted Profit After Extra-ordinary item  | -27.68  | -16.68  | -9.38  | -25.26  | -40.46  | 
EPS (Unit Curr.)  | 0.46  | -1.8  | 0  | 0.44  | 1.09  | 
Book Value (Unit Curr.)  | 0  | 0  | 0  | 0  | 0  | 
Dividend (%)  | 0  | 0  | 0  | 0  | 0  | 
Equity  | 6.13  | 6.13  | 6.13  | 6.13  | 6.13  | 
Public Shareholding (Number)  | 0  | 0  | 0  | 0  | 0  | 
Public Shareholding (%)  | 0  | 0  | 0  | 0  | 0  | 
Pledged/Encumbered - No. of Shares  | 0  | 0  | 0  | 0  | 0  | 
Pledged/Encumbered - % in Total Promoters Holding  | 0  | 0  | 0  | 0  | 0  | 
Pledged/Encumbered - % in Total Equity  | 0  | 0  | 0  | 0  | 0  | 
Non Encumbered - No. of Shares  | 0  | 0  | 0  | 0  | 0  | 
Non Encumbered - % in Total Promoters Holding  | 0  | 0  | 0  | 0  | 0  | 
Non Encumbered - % in Total Equity  | 0  | 0  | 0  | 0  | 0  | 
PBIDTM(%)  | 8.02  | 2.64  | 5.51  | 9.53  | 25.33  | 
PBDTM(%)  | -  | -  | -  | -  | -  | 
PATM(%)  | 0.82  | -4.24  | -1.46  | 0.98  | 2.74  | 
Such a contract symbolizes Panacea Biotec's continued commitment toward global health by contributing its share of the fight against polio, a deadly disease prevalent in many pockets of the world.
Panacea Biotec's stock has seen a 37% gain over the past six months. Panacea Biotec's stock has gained a total of 76% in the last one year.
 IIFL Customer Care Number 
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000  / 7039-050-000
 IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.